Replies to post #104307 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

My memory is IMUC phase II enrolled rapids and pseudoprogressors -- I think the CEO confirmed this -- although their exclusion of recurrent disease makes the former a little nebulous. Their trial was comparatively hurt by keeping rapids, their trial was comparatively helped by keeping psPD. In the phase III the:

Subjects must be in primary remission

In their new Phase III trial, they went more with NWBO's placebo type, PBMC. (Instead of ICT-107's prior trial using active unpulsed dendritic cells)